TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change in carotid intima-media thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in flow mediated dilatation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in Diffusion Tensor Imaging (DTI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in Test of Arm Selective Control (TASC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Selective Control Assessment of the Lower Extremity (SCALE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levator ani injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Percent of Confirmed Tumor Responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percent of Correct and Incorrect Mohs Quiz Responses
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Rapid plasma regain titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pH of blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major Immunoglobulin E-binding epitope on wheat proteins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Virologic Response (HIV-1 RNA < 50 Copies/mL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Airway failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Influenza vaccination rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Prevalence of constrained insert use in primary total knee arthroplasty
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: family decision-making self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of patients receiving post-ED follow-up
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Proportion of patients with documented mental health recommendations
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Gross Motor Function Measure Dimension D and E
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants who develop anti-drug antibody to AGA111
Endpoint domain: Adverse events/effects
Primary endpoint: Preparedness for caregiving
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Adherence to immunosuppressant medications (self-report)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to immunosuppressant medications (blood levels)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distribution of adipocyte mitochondria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Intubation successful rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Disease-Specific Health-Related Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Total Bacterial Load in the Sputum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Anastomotic stricture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Weight-for-height Z-score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: sensitivity of peroneal nerve test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: specificity of peroneal nerve test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in DPD (Deoxypyridinoline)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in OSC (Osteocalcin)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of items properly recalled
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Unoccluded retinal vessel diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Social Competence and Behavioral Evaluation (SCBE) scores overall
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Social Competence and Behavioral Evaluation (SCBE) aggression subscale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Social Competence and Behavioral Evaluation (SCBE) prosocial subscale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Sympathetic activity in MDD patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in total and trabecular volumetric BMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Prevalence of CKD complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Biomarkers of kidney function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Severity of depressive symptoms - clinical rating
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of depressive symptoms - self-report
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of patients who are alive without radiological progression
Endpoint domain: Mortality/survival
Primary endpoint: Changes in brain biomarkers due to sub-concussion injury - Nf-L
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in brain biomarkers due to sub-concussion injury - Tau
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in brain biomarkers due to sub-concussion injury - UCH-L1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in sub-concussion injury related inflammation biomarkers - CRP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in sub-concussion injury related inflammation biomarkers - TNF-α
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: All-cause mortality at day 28
Endpoint domain: Mortality/survival
Primary endpoint: change in Pocket Probing Depth (cPPD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptability of Intervention Measure
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change From Baseline in Ashworth Scale (AS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Investigator's Global Impression of Change Scale (GICS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Positive findings in the physical examination of the temporomandibular joint and muscles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to the presence of bowel sound
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Time to the first passage of flatus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Time to the first passage of stool
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Time to the start of regular diet
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in Vibration Frequency Detection Threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Pain Threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Hypersensitivity to Von Frey Filament
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Socialization
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Pain Intensity on Movement Evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Surgical Site Healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Threshold value of sound velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of Participants to Complete Model Adapted Radiations Fractionation Scheduled
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change from baseline in 24-hour urinary glucose excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Global response assessment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rates of traffic offenses
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Migraine Interictal Burden Scale (MIBS-4) Scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percent Change of GABA Concentration in Left Motor Cortex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percent Change of GABA Concentration in Right Motor Cortex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percent Change of Functional Connectivity in Left Motor Cortex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percent Change of Functional Connectivity in Right Motor Cortex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Blood Phe level decrease by 30%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: MRS
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Residual Cancer Burden Grade III (RCB-III)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Diagnostic Accuracy of the electronic nose signal value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Average Days needed to observe a negative result
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PrEP Adherence Defined by Tenofovir Diphosphate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PrEP Adherence Defined by Emtricitabine Triphosphate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of chest tube placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Effect on renal function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Subluxation degree by physical examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subluxation degree by radiograph
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ostomy Adjustment Scale measurement of quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Reduction of sEMG activity of masseter muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Hospitalisations for cardiovascular disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 6 week disease control rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Plasma Glucose Area Under the Curve (AUC 0-3h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change of accuracy rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the amplitude of ERP recording
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Progression of TR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Mean Change in Bone Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Biomechanical complications
Endpoint domain: Adverse events/effects
Primary endpoint: Progression Free Survival 2 (PFS 2)
Endpoint domain: Mortality/survival
Primary endpoint: Serious Adverse Events Related to Treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Muscle mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Maximum Respiratory Pressures (MIP and MEP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Handgrip strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Components of metabolic syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Retinal layer thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Use of safe sleep environment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Interstitial Cystitis Symptom Improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Blood pressure at two hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinite Time (AUCinf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evoked activity for imaging effectiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Clinical Outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of subjects with HIV-1 RNA less than 400 copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in Self-reported Frequency of Cannabis Use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Self-reported Motivation to Reduce Cannabis Use (SOCRATES)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Self-reported Motivation to Reduce Cannabis Use (Readiness Ruler)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Self-reported Motivation to Reduce Cannabis Use (DBI)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Participants With Worsening of COVID-19 Within 28 Days
Endpoint domain: Mortality/survival
Primary endpoint: Rates of participant completion of symptom reports
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Fat Storage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Non-lethal myocardial infarction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Modified clinical test of sensory interaction in balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anti-hepatitis B Surface Antigen HBsAg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Serum Anti-polyribosylribitol Phosphate PRP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Suppression of gonadotropin and pituitary hormones
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change from baseline in serum creatinine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Sternal wound infection condition on postoperative day 7
Endpoint domain: Adverse events/effects
Primary endpoint: Sternal wound infection condition on postoperative day 30
Endpoint domain: Adverse events/effects
Primary endpoint: Sternal wound infection condition on postoperative day 90
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major Adverse Cardiovascular and Cerebral Events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Motricity index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fugl-Meyer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Action Research arm test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Motor Activity log
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Jamar handgrip strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum tolerated dose of capecitabine
Endpoint domain: Adverse events/effects
Primary endpoint: Left Ventricular End Diastolic Volume Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: End of life preference
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Proportion of diabetic patients obtaining retina eye exam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC of BAY1834845 after oral administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of BAY1834845 after oral administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total body clearance (CL) of BAY1834845 after intravenous administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of adverse events by type, frequency, severity, and causality
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of treatment-emergent adverse events by type, frequency, severity, and causality
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of serious adverse events by type, frequency, severity, and causality
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum tolerated dose (MTD) of panobinostat
Endpoint domain: Adverse events/effects
Primary endpoint: Dose-limiting toxicity (MTD) of Panobinostat
Endpoint domain: Adverse events/effects
Primary endpoint: Treatment response to antifungal therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: amount of drugs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: drugs used time
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: numbers of muscular fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: degree of inflammation reaction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: adrenal function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Intraocular IOL position
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentual success of the procedure during hospitalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentual success of the procedure at 3 months from procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentual success of the procedure at 6 months from procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Child Drawing: Hospital (CD: H) scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Human Figure Drawings (HFD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frankl Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sound, Eye, and Motor (SEM) scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: neostomach volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: subjects' weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of volume change of whole brain, hippocampus and other structural MRI measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Decline as measured by: Cognitive Tests, Activities of Daily Living, and CDR Sum of Boxes
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Rates of change of glucose metabolism (FDG-PET)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Risk-Taking
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: aberrant drug-related behavior
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of Clinically Acceptable Performance of Remote Control Functionality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hs-C reactive protein (hsCRP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: vascularization index (VI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: uterine doppler
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: flow index (FI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: vascularization flow index (VFI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Seizure occurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proportion of men abstaining from anal and vaginal intercourse
Endpoint domain: Life impact
Endpoint subdomain: Sexual functioning